Bengaluru, India

Kumaravel Selvakumar

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2013-2025

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):

Title: Kumaravel Selvakumar: Innovating Pharmaceutical Solutions in Bengaluru

Introduction

Kumaravel Selvakumar, a distinguished inventor based in Bengaluru, India, has made significant contributions to the field of pharmaceutical sciences. With a total of 10 patents to his name, Kumaravel has focused on developing innovative compounds that target various health issues, particularly those associated with αV integrin inhibitors.

Latest Patents

Kumaravel's recent inventions include groundbreaking patents that explore the utility of 3-substituted propionic acids and cyclobutanes- and azetidine-containing compounds as αV integrin inhibitors. The first patent centers on compounds of Formula (I) that act as antagonists to α-containing integrins. These compounds can lead to pharmaceutical compositions aimed at treating diseases linked to the dysregulation of α-containing integrins, including pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. The second patent similarly revolves around the compounds of Formula (I), further contributing to the understanding and treatment possibilities for conditions related to αV-containing integrins.

Career Highlights

Throughout his career, Kumaravel has aligned himself with notable companies in the pharmaceutical sector. He has worked with Bristol-Myers Squibb Company and Syngene International Limited, where he further honed his skills in drug development and innovation. His expertise in creating effective pharmaceutical solutions continues to impact the industry significantly.

Collaborations

Kumaravel has collaborated with esteemed colleagues such as Suresh Dhanusu and Peter Tai Wah Cheng, working together to drive advancements in the development of integrin-targeted therapies. These professional relationships have fostered a collaborative environment that has been pivotal in achieving successful patented innovations.

Conclusion

Kumaravel Selvakumar represents the forefront of innovation in pharmacological inventions. Through his 10 patents, particularly in developing integrin inhibitors, he continues to contribute to addressing critical health issues. His work is not only a testament to his inventiveness but also to the power of collaboration in achieving significant breakthroughs in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…